DR. SYLVIA JARAMILLO MD NPI 1407089642

NPI Details

DR. Sylvia Jaramillo, MD is a medical oncology internal medicine in Austin, TX with 17 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Sylvia Jaramillo, MD NPI is 1407089642. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UNIVERSITY OF UTAH SCHOOL OF MEDICINE
Graduation Year:2009

The provider's business location address is:

12221 RENFERT WAY
SUITE 300
AUSTIN, TX
ZIP 78758-444
Phone: (512) 873-8900
Fax: (512) 834-8676

The NPI 1407089642 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Unclassified drugs (HCPCS:J3490)
• Folic acid level, serum (HCPCS:82746)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Thyroid hormone, t3 measurement, free (HCPCS:84481)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Immunologic analysis technique on serum (HCPCS:86320)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Protein measurement, serum (HCPCS:84165)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, lorazepam, 2 mg (HCPCS:J2060)
• Drawing of blood for a medical problem (HCPCS:99195)
• Manual urinalysis test with examination using microscope, non-automated (HCPCS:81000)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Red blood count, automated test (HCPCS:85045)

The enumeration date for this NPI number is 9/3/2009 and was last updated on 10/23/2017.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.